113 related articles for article (PubMed ID: 20420818)
1. Standard warfarin dose in a patient with the CYP2C9*3/*3 genotype leads to hematuria.
Goto T; Miura M; Murata A; Terata K; Uno T; Yamamoto K; Abe Y
Clin Chim Acta; 2010 Sep; 411(17-18):1375-7. PubMed ID: 20420818
[TBL] [Abstract][Full Text] [Related]
2. Gene-based warfarin dosing compared with standard of care practices in an orthopedic surgery population: a prospective, parallel cohort study.
McMillin GA; Melis R; Wilson A; Strong MB; Wanner NA; Vinik RG; Peters CL; Pendleton RC
Ther Drug Monit; 2010 Jun; 32(3):338-45. PubMed ID: 20386359
[TBL] [Abstract][Full Text] [Related]
3. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin.
Kamali F; Khan TI; King BP; Frearson R; Kesteven P; Wood P; Daly AK; Wynne H
Clin Pharmacol Ther; 2004 Mar; 75(3):204-12. PubMed ID: 15001972
[TBL] [Abstract][Full Text] [Related]
4. Low dose requirement for warfarin treatment in a patient with CYP2C9*3/*13 genotype.
Kwon MJ; On YK; Huh W; Ko JW; Kim DK; Kim JS; Lee SY
Clin Chim Acta; 2011 Nov; 412(23-24):2343-5. PubMed ID: 21782804
[TBL] [Abstract][Full Text] [Related]
5. Several-fold increase in risk of overanticoagulation by CYP2C9 mutations.
Lindh JD; Lundgren S; Holm L; Alfredsson L; Rane A
Clin Pharmacol Ther; 2005 Nov; 78(5):540-50. PubMed ID: 16321620
[TBL] [Abstract][Full Text] [Related]
6. CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy.
Peyvandi F; Spreafico M; Siboni SM; Moia M; Mannucci PM
Clin Pharmacol Ther; 2004 Mar; 75(3):198-203. PubMed ID: 15001971
[TBL] [Abstract][Full Text] [Related]
7. [The influence of CYP2C9 genetic polymorphism on the pharmacokinetics and pharmacodynamics of warfarin in patients with constant atrial fibrillation].
Sychev DA; Mikheeva IuA; Kropacheva ES; Ignat'ev IV; Bulytova IuM; Ramenskaia GV; Dobrovol'skiĭ AB; Panchenko EP; Kukes VG
Klin Med (Mosk); 2007; 85(1):57-60. PubMed ID: 17419358
[TBL] [Abstract][Full Text] [Related]
8. Impact of CYP2C9 genetic polymorphism on warfarin dose requirements in Pakistani population.
Siddiqi A; Khan DA; Khan FA; Naveed AK
Pak J Pharm Sci; 2010 Oct; 23(4):417-22. PubMed ID: 20884456
[TBL] [Abstract][Full Text] [Related]
9. Potential glucosamine-warfarin interaction resulting in increased international normalized ratio: case report and review of the literature and MedWatch database.
Knudsen JF; Sokol GH
Pharmacotherapy; 2008 Apr; 28(4):540-8. PubMed ID: 18363538
[TBL] [Abstract][Full Text] [Related]
10. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study.
Caraco Y; Blotnick S; Muszkat M
Clin Pharmacol Ther; 2008 Mar; 83(3):460-70. PubMed ID: 17851566
[TBL] [Abstract][Full Text] [Related]
11. Interindividual variability in sensitivity to warfarin--Nature or nurture?
Loebstein R; Yonath H; Peleg D; Almog S; Rotenberg M; Lubetsky A; Roitelman J; Harats D; Halkin H; Ezra D
Clin Pharmacol Ther; 2001 Aug; 70(2):159-64. PubMed ID: 11503010
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation.
Tàssies D; Freire C; Pijoan J; Maragall S; Monteagudo J; Ordinas A; Reverter JC
Haematologica; 2002 Nov; 87(11):1185-91. PubMed ID: 12414349
[TBL] [Abstract][Full Text] [Related]
13. [Warfarin in the treatment of antiphospholipid syndrome].
Reshetniak TM; Kondrat'eva LV; Patrusheva NL; Patrushev LI
Ter Arkh; 2007; 79(5):47-54. PubMed ID: 17672075
[TBL] [Abstract][Full Text] [Related]
14. [Significance of cytochrome P450 2C9 genotype for the bleeding complications in patients treated with acenocoumarol].
Márk L; Márki-Zay J; Fodor L; Kondacs A; Paragh G; Katona A
Orv Hetil; 2005 Apr; 146(16):739-43. PubMed ID: 15889670
[TBL] [Abstract][Full Text] [Related]
15. Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status.
Schalekamp T; Oosterhof M; van Meegen E; van Der Meer FJ; Conemans J; Hermans M; Meijerman I; de Boer A
Clin Pharmacol Ther; 2004 Nov; 76(5):409-17. PubMed ID: 15536456
[TBL] [Abstract][Full Text] [Related]
16. Acenocoumarol stabilization is delayed in CYP2C93 carriers.
Schalekamp T; van Geest-Daalderop JH; de Vries-Goldschmeding H; Conemans J; Bernsen Mj Mj; de Boer A
Clin Pharmacol Ther; 2004 May; 75(5):394-402. PubMed ID: 15116052
[TBL] [Abstract][Full Text] [Related]
17. A case report of a patient carrying CYP2C9*3/4 genotype with extremely low warfarin dose requirement.
Lee SY; Nam MH; Kim JS; Kim JW
J Korean Med Sci; 2007 Jun; 22(3):557-9. PubMed ID: 17596671
[TBL] [Abstract][Full Text] [Related]
18. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation.
Hylek EM; Skates SJ; Sheehan MA; Singer DE
N Engl J Med; 1996 Aug; 335(8):540-6. PubMed ID: 8678931
[TBL] [Abstract][Full Text] [Related]
19. A randomized trial of genotype-guided dosing of warfarin.
Pirmohamed M; Burnside G; Eriksson N; Jorgensen AL; Toh CH; Nicholson T; Kesteven P; Christersson C; Wahlström B; Stafberg C; Zhang JE; Leathart JB; Kohnke H; Maitland-van der Zee AH; Williamson PR; Daly AK; Avery P; Kamali F; Wadelius M;
N Engl J Med; 2013 Dec; 369(24):2294-303. PubMed ID: 24251363
[TBL] [Abstract][Full Text] [Related]
20. A novel sequence variant in exon 7 of CYP2C9 gene (CYP2C9*24) in a patient on warfarin therapy.
Herman D; Peternel P; Stegnar M; Breskvar K; Dolzan V
Thromb Haemost; 2006 Jan; 95(1):192-4. PubMed ID: 16543980
[No Abstract] [Full Text] [Related]
[Next] [New Search]
